File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nanoparticulate Drug Delivery to the Retina

TitleNanoparticulate Drug Delivery to the Retina
Authors
Keywordsnanoparticle
retinal diseases
ocular delivery
ocular barriers
delivery efficiency
Issue Date2020
PublisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/mpohbp/index.html
Citation
Molecular Pharmaceutics, 2020, Epub 2020-06-05 How to Cite?
AbstractRetinal diseases, such as age-related macular degeneration and diabetic retinopathy, are the leading causes of blindness worldwide. The mainstay of treatment for these blinding diseases remains to be surgery, and the available pharmaceutical therapies on the market are limited, partially owing to various biological barriers in hindering the delivery of therapeutics to the retina. The nanoparticulate drug delivery system confers the capability for delivering therapeutics to the specific ocular targets and, hence, potentially revolutionizes the current treatment landscape of retinal diseases. While the research to date indicates the enormous therapeutics potentials of the nanoparticulate delivery systems, the successful translation of these systems from the bench to bedside is challenging and requires a combined understanding of retinal pathology, physiology of the eye, and particle and formulation designs of nanoparticles. To this end, the review begins with an overview of the most prevalent retinal diseases and related pharmacotherapy. Highlights of the current challenges encountered in ocular drug delivery for each administration route are provided, followed by critical appraisal of various nanoparticulate drug delivery systems for the retinal diseases, including their formulation designs, therapeutic merits, limitations, and future direction. It is believed that a greater understanding of the nano-biointeraction in eyes will lead to the development of more sophisticated drug delivery systems for retinal diseases.
Persistent Identifierhttp://hdl.handle.net/10722/283271
ISSN
2019 Impact Factor: 4.321
2015 SCImago Journal Rankings: 1.681

 

DC FieldValueLanguage
dc.contributor.authorLI, Q-
dc.contributor.authorWENG, J-
dc.contributor.authorWONG, SN-
dc.contributor.authorLEE, WYT-
dc.contributor.authorChow, SF-
dc.date.accessioned2020-06-22T02:54:23Z-
dc.date.available2020-06-22T02:54:23Z-
dc.date.issued2020-
dc.identifier.citationMolecular Pharmaceutics, 2020, Epub 2020-06-05-
dc.identifier.issn1543-8384-
dc.identifier.urihttp://hdl.handle.net/10722/283271-
dc.description.abstractRetinal diseases, such as age-related macular degeneration and diabetic retinopathy, are the leading causes of blindness worldwide. The mainstay of treatment for these blinding diseases remains to be surgery, and the available pharmaceutical therapies on the market are limited, partially owing to various biological barriers in hindering the delivery of therapeutics to the retina. The nanoparticulate drug delivery system confers the capability for delivering therapeutics to the specific ocular targets and, hence, potentially revolutionizes the current treatment landscape of retinal diseases. While the research to date indicates the enormous therapeutics potentials of the nanoparticulate delivery systems, the successful translation of these systems from the bench to bedside is challenging and requires a combined understanding of retinal pathology, physiology of the eye, and particle and formulation designs of nanoparticles. To this end, the review begins with an overview of the most prevalent retinal diseases and related pharmacotherapy. Highlights of the current challenges encountered in ocular drug delivery for each administration route are provided, followed by critical appraisal of various nanoparticulate drug delivery systems for the retinal diseases, including their formulation designs, therapeutic merits, limitations, and future direction. It is believed that a greater understanding of the nano-biointeraction in eyes will lead to the development of more sophisticated drug delivery systems for retinal diseases.-
dc.languageeng-
dc.publisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/mpohbp/index.html-
dc.relation.ispartofMolecular Pharmaceutics-
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in [JournalTitle], copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles on Request author-directed link to Published Work, see http://pubs.acs.org/page/policy/articlesonrequest/index.html].-
dc.subjectnanoparticle-
dc.subjectretinal diseases-
dc.subjectocular delivery-
dc.subjectocular barriers-
dc.subjectdelivery efficiency-
dc.titleNanoparticulate Drug Delivery to the Retina-
dc.typeArticle-
dc.identifier.emailChow, SF: asfchow@hku.hk-
dc.identifier.authorityChow, SF=rp02296-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1021/acs.molpharmaceut.0c00224-
dc.identifier.hkuros310386-
dc.identifier.volumeEpub 2020-06-05-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats